guest ::
| Home > Publications Database > Advances in cognitive testing |
| Home > Publications Database > Advances in cognitive testing |
| Contribution to a book | DZNE-2025-00654 |
2025
Elsevier
This record in other databases:
Please use a persistent id in citations: doi:10.1016/B978-0-12-822240-9.00009-0
Abstract: Recent developments in Alzheimer's disease biomarkers have significantly improved the early detection of Alzheimer's disease pathology (Hansson et al., 2023; Ossenkoppele and Hansson, 2021; Zetterberg and Blennow, 2021) [1-3]. However, while biomarkers for Alzheimer's disease can indicate the underlying brain pathology and have some predictive value for future cognitive decline, they do not provide information about cognitive Alzheimer's disease phenotypes, particularly in early disease stages (Dubois et al., 2021) [4], nor do they represent optimal measures of disease progression. Thus, it is of critical importance to identify, characterize, and monitor cognitive impairment in Alzheimer's disease using cognitive assessments. While capturing subtle cognitive changes and impairment in early disease stages still remains challenging (Weintraub et al., 2018) [5], several new approaches have recently been utilized to improve the early detection of subtle cognitive impairment and decline. In this chapter, I will first provide an overview of novel cognitive test paradigms that are tailored toward cognitive functions of which the functional anatomy overlaps with spatial patterns of accumulation of Alzheimer's disease pathology; these paradigms aim to capture signs of early impairment with greater sensitivity than previous measures. I will then illustrate new approaches to cognitive testing that build on recent technological developments (Koo and Vizer, 2019; Kourtis et al., 2019) [6,7] and aim to assess cognitive performance even outside clinical settings.
|
The record appears in these collections: |
PDF
PDF (PDFA)